Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pathologic Complete Response 1 Colorectal Neoplasms 1 Carcinoma, Neuroendocrine 1

Interventions

Nivolumab 6 atezolizumab 5 Cisplatin 5 Ipilimumab 4 Carboplatin 4 Etoposide 3 pembrolizumab 2 gallium Ga 68 dotatate 2 dostarlimab 2 Temozolomide 2 Positron Emission Tomography Computed Tomography 2 Paclitaxel 2 Magnetic Resonance Imaging 2 Irinotecan 2 Immunoglobulin G 2 IFL protocol 2 Disulfides 2 zimberelimab 1 tivozanib 1 repotrectinib 1 niraparib 1 lutetium Lu 177 dotatate 1 lenvatinib 1 iadademstat 1 durvalumab 1 cabozantinib 1 budigalimab 1 belinostat 1 Topotecan 1 Standard of Care 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × FOLFOXIRI protocol × 1 year × Clear all

NCT04325425 2025-09-30

FOLFIRINEC

Centre Hospitalier Universitaire Dijon

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡